Do we need prophylactic anticoagulation in ambulatory patients with lung cancer? A review. (June 2020)

• Record Type: Journal Article
• Authors: Dimakakos, Evangelos; Kotteas, Elias; Gomatou, Georgia; Katsarou, Theodora; Vlahakos, Vassilis; Vathiotis, Ioannis; Talagani, Sofia; Dimitroulis, Ioannis; Syrigos, Konstantinos
• Is Part Of: Vascular medicine. Volume 25:Number 3(2020)
• Page Start: 255
• Page End: 262
• Publication Date: 2020-06
• Subjects: lung cancer -- prophylactic anticoagulation -- pulmonary embolism (PE) -- risk assessment models -- venous thromboembolism (VTE); Blood-vessels -- Diseases -- Periodicals; Peripheral vascular diseases -- Periodicals; Vascular Diseases -- Periodicals; Vaisseaux sanguins -- Maladies -- Périodiques; Maladies vasculaires périphériques -- Périodiques; 616.13
• DOI: 10.1177/1358863X19899160
• Languages: English
• ISSNs: 1358-863X

Abstract

Venous thromboembolism is a common complication of malignancy. Lung cancer is considered one of the most thrombogenic cancer types. Primary thromboprophylaxis is not currently recommended for all ambulatory patients with active cancer. In the present narrative review we aim to summarize recent data on the safety and efficacy of primary thromboprophylaxis as well as on venous thromboembolism risk assessment, focusing on ambulatory patients with lung cancer. A potential benefit from prophylactic anticoagulation with low molecular weight heparins in terms of venous thromboembolism risk reduction and increased overall survival in patients with lung cancer, without a significant increase in bleeding risk, has been reported in several studies. Recent studies also reveal promising results of direct oral anticoagulants regarding their efficacy as primary thromboprophylaxis in patients with cancer, including those with lung cancer. However, the use of different study methodologies and the heterogeneity of study populations among the trials limit the extraction of definite results. More randomized, controlled trials, restricted to a well-characterized population of patients with lung cancer, are greatly anticipated. The use of risk assessment tools for stratification of venous thromboembolic risk is warranted. The development of an accurate and practical risk assessment model for patients with lung cancer represents an unmet need.